Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million ...
Among patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, neoadjuvant FOLFIRINOX showed comparable overall survival to neoadjuvant gemcitabine-based chemoradiotherapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results